About Survodutide
Survodutide is studied as a dual GLP-1 receptor and glucagon receptor agonist in metabolic research. Supplied as a lyophilized powder for laboratory investigations into incretin/glucagon receptor pharmacology and energy-metabolism pathway markers in controlled experimental models. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Recent research on Survodutide: Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Read Full Study on PubMedDual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Recent research on Survodutide: Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Read Full Study on PubMedAdditional Studies
Pharmacological management of obesity: Current landscape and emerging therapies.
Recent research on Survodutide: Pharmacological management of obesity: Current landscape and emerging therapies.
Read on PubMedAuthor Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Recent research on Survodutide: Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Read on PubMedSurvodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).
Recent research on Survodutide: Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).
Read on PubMedCardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.
Recent research on Survodutide: Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.
Read on PubMedAnti-Obesity Medications in Longevity and Aesthetic Medicine.
Recent research on Survodutide: Anti-Obesity Medications in Longevity and Aesthetic Medicine.
Read on PubMedWeight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Recent research on Survodutide: Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Read on PubMedRelated Research
Purchase Survodutide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.